[1] [1] Berezin AE, Berezin AA. Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers[J]. Dis Markers, 2020, 2020:1215802.

[2] [2] Groenland FTW, Neleman T, Kakar H, et al. Intravascular ultrasound-guided versus coronary angiography-guided percutaneous coronary intervention in patients with acute myocardial infarction: A systematic review and meta-analysis[J]. Int J Cardiol, 2022, 353:35-42.

[3] [3] Marquis-Gravel G, Zeitouni M, Kochar A, et al. Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies[J]. Catheter Cardiovasc Interv, 2020, 95(5):924-931.

[4] [4] Lpez-Castillo M, Acea , Pello-Lzaro AM, et al. Prognostic value of initial QRS analysis in anterior STEMI: Correlation with left ventricular systolic dysfunction, serum biomarkers, and cardiac outcomes[J]. Ann Noninvasive Electrocardiol, 2021, 26(1):e12791.

[5] [5] Giralt T, Ribas N, Freixa X, et al. Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter[J]? Int J Cardiol, 2021, 325:9-15.

[6] [6] Raghuram K, Deepanjali S, Ananthakrishna Pillai A. Factors associated with normal flow (TIMI 3) after thrombolysis with streptokinase in ST-elevation myocardial infarction: A prospective observational study[J]. Cureus, 2021, 13(1):e12758.

[7] [7] Allahwala UK, Nour D, Alsanjari O, et al. Prognostic implications of the rapid recruitment of coronary collaterals during ST elevation myocardial infarction (STEMI): a meta-analysis of over 14,000 patients[J]. J Thromb Thrombolysis, 2021, 51(4):1005-1016.

[8] [8] Liu F, Cui B, Zhao X, et al. Correlation of serum adropin levels with risk factors of cardiovascular disease in hemodialysis patients[J]. Metab Syndr Relat Disord, 2021, 19(7):401-408.

[9] [9] Bozic J, Kumric M, Ticinovic Kurir T, et al. Role of adropin in cardiometabolic disorders: from pathophysiological mechanisms to therapeutic target[J]. Biomedicines, 2021, 9(10):1407.

[10] [10] Mushala BAS, Scott I. Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism[J]. Am J Physiol Heart Circ Physiol, 2021, 320(1):H238-H244.

[11] [11] Erdol MA, Ertem S, Ertem AG, et al. Adropin: Connection between nonalcoholic fatty liver disease and coronary artery disease[J]. Med Princ Pract, 2020, 29(1):97.

[12] [12] Yang M, Pei Q, Zhang J, et al. Association between adropin and coronary artery lesions in children with Kawasaki disease[J]. Eur J Pediatr, 2021, 180(7):2253-2259.

[14] [14] Kim HK, Ahn Y, Chang K, et al. 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction[J]. Korean Circ J, 2020, 50(10):845-866.

[17] [17] Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study[J]. Circulation, 1986, 74(3):469-476.

[18] [18] Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention[J]. J Invasive Cardiol, 2010, 22(10 Suppl B):6B-14B.

[19] [19] Alsanjari O, Chouari T, Williams T, et al. Angiographically visible coronary artery collateral circulation improves prognosis in patients presenting with acute ST segment-elevation myocardial infarction[J]. Catheter Cardiovasc Interv, 2020, 96(3):528-533.

[22] [22] Yetkin E, Yalta K. Existence of coronary collateral vessels during acute myocardial infarction[J]. Heart Vessels, 2023, 38(1):136-137.

[23] [23] Chu AA, Li W, Zhu YQ, et al. Effect of coronary collateral circulation on the prognosis of elderly patients with acute ST-segment elevation myocardial infarction treated with underwent primary percutaneous coronary intervention[J]. Medicine (Baltimore), 2019, 98(31):e16502.

[25] [25] Xia SL, Tao HK, Ma L, et al. Pre-operative evaluation and mid-term outcomes of anomalous origin of the left coronary artery from the pulmonary artery based on left ventricular ejection fraction[J]. Front Cardiovasc Med, 2022, 9:961491.

[27] [27] Jasaszwili M, Billert M, Strowski MZ, et al. Adropin as a fat-burning hormone with multiple functions-review of a decade of research[J]. Molecules, 2020, 25(3):549.

[28] [28] Banerjee S, Ghoshal S, Stevens JR, et al. Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction[J]. J Biol Chem, 2020, 295(40):13753-13768.

[29] [29] Chang X, Jin F, Wang L, et al. Adropin: A new player in energy regulation predicts long-term prognosis of patients with acute myocardial infarction[J]. Heliyon, 2023, 9(7):e17803.

[30] [30] Vural A, Kurt D, Karagz A, et al. The relationship between coronary collateral circulation and serum adropin levels[J]. Cureus, 2023, 15(2):e35166.